Citation: Rg. Oganov et Ng. Kiseleva, Sterols and stanols of plant origin: new prospects in prevention of ischemic heart disease, TERAPEVT AR, 73(1), 2001, pp. 33-38
Citation: Nv. Perova et al., Cluster of metabolic syndrome factors: Pathogenetic interrelationships andapproaches to correction, KARDIOLOGIY, 41(3), 2001, pp. 4-9
Citation: Rg. Oganov et Nm. Akhmedzhanov, Atorvastatin - Novel inhibitor of HMG CoA reductase for the treatment of atherosclerosis and dyslipidemia, KARDIOLOGIY, 40(7), 2000, pp. 62-67
Citation: Rg. Oganov et Gy. Maslennikova, Cardiovascular diseases in Russian Federation in the second half of the twentieth century: Tendencies, possible causes, perspectives, KARDIOLOGIY, 40(6), 2000, pp. 4-8
Citation: Nm. Akhmedzhanov et al., Lipid lowering activity of cerivastatin in patients with ischemic heart disease, KARDIOLOGIY, 40(12), 2000, pp. 50-55
Authors:
Mamedov, MN
Perova, NV
Metelskaya, VA
Oganov, RG
Citation: Mn. Mamedov et al., Interrelation of abdominal type of obesity and syndrome of insulin resistance in patients with hypertension, KARDIOLOGIY, 39(9), 1999, pp. 18-22
Authors:
Sidorenko, BA
Oganov, RG
Arabidze, GG
Karpov, YA
Doshchitsin, VL
Ivleva, AY
Gratsianskii, NA
Kobalava, ZD
Citation: Ba. Sidorenko et al., The trends in treatment of cardiovascular diseases in the XXI century: Role of angiotensin II blockers receptors - Discussion, KARDIOLOGIY, 39(6), 1999, pp. 86-96
Authors:
Oganov, RG
Perova, NV
Mamedov, MN
Metelskaya, VA
Citation: Rg. Oganov et al., Combination of the metabolic syndrome components in patients with arterialhypertension and their relationship with dyslipidemia, TERAPEVT AR, 70(12), 1998, pp. 19-23
Authors:
Metelitsa, VI
Martsevich, SY
Kozyreva, MP
Oganov, RG
Citation: Vi. Metelitsa et al., Nitrate tolerance: New data on mechanism of development and possibilities of correction, KARDIOLOGIY, 38(12), 1998, pp. 56-63